Carnegie Investment Counsel’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $763K | Hold |
82,778
| – | – | 0.02% | 331 |
|
|
2025
Q1 | $690K | Buy |
82,778
+6,000
| +8% | +$50K | 0.02% | 328 |
|
|
2024
Q4 | $825K | Buy |
76,778
+3,445
| +5% | +$37K | 0.02% | 279 |
|
|
2024
Q3 | $417K | Hold |
73,333
| – | – | 0.01% | 362 |
|
|
2024
Q2 | $309K | Hold |
73,333
| – | – | 0.01% | 400 |
|
|
2024
Q1 | $373K | Sell |
73,333
-327
| -0.4% | -$1.66K | 0.01% | 395 |
|
|
2023
Q4 | $686K | Buy |
73,660
+6,250
| +9% | +$58.2K | 0.02% | 321 |
|
|
2023
Q3 | $442K | Sell |
67,410
-650
| -1% | -$4.26K | 0.02% | 363 |
|
|
2023
Q2 | $553K | Buy |
68,060
+24,385
| +56% | +$198K | 0.02% | 334 |
|
|
2023
Q1 | $374K | Buy |
43,675
+24,925
| +133% | +$214K | 0.01% | 395 |
|
|
2022
Q4 | $174K | Buy |
+18,750
| New | +$174K | 0.01% | 497 |
|